IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today reiterated the Company’s concern regarding Valeant Pharmaceuticals International, Inc.’s (“Valeant”) unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operational excellence. A number of different third parties have also publicly expressed similar views.
Help employers find you! Check out all the jobs and post your resume.
